NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, PhD, as the Company's Vice President, Chemistry, Manufacturing and Control (CMC). In addition, Paul Brennan has joined the NervGen team to...
2019-05-30 9:00 AM EDT
NervGen Pharma Commences Trading on OTCQB
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading on the TSX Venture Exchange, its common shares will commence trading today on the OTCQB Venture Market under the symbol "NGENF". "The commencement of...
2019-05-03 9:00 AM EDT
NervGen Pharma to Ring the Opening Bell of Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that the Company will ring the opening bell at Toronto Stock Exchange tomorrow morning to celebrate its listing on March 13, 2019. "As the Company continues to broaden its support in the...
2019-05-01 2:26 PM EDT
NervGen Pharma's Patent Estate Grows with the Addition of US Patents for Its Groundbreaking Nerve Regeneration Technology
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - NervGen Pharma Corp. ("NervGen"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTPσ
2019-04-24 9:00 AM EDT
Amended: NervGen Pharma Increases Private Placement to $740,000
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $740,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) and 300,000 shares at $1.30 each (new). The net...
2019-04-23 6:08 PM EDT
NervGen Pharma Increases Private Placement to $650,000
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $650,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) and 300,000 shares at $1.30 each (new)....
2019-04-22 4:02 PM EDT
NervGen Pharma Appoints Amy Franke as VP, Clinical Operations
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Amy Franke as the Company's Vice President, Clinical Operations. "With the recent successful completion of our Initial Public Offering, we are fully focused on driving our lead drug candidate, NVG-291, into clinical...
2019-04-01 8:30 AM EDT
NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 - Symbol "NGEN"
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering ("IPO") of its common shares and listing as a Tier 2 company on the TSX Venture Exchange ("TSX-V"). The IPO consisted of the issuance of 10,000,000 common shares of the Company at a price of $1.00 per...
2019-03-13 3:52 PM EDT